ROCKVILLE, Md. & EDMONTON, Alberta / Jul 02, 2024 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will participate in one-on-one meetings with investors at the Leerink Partners Therapeutics Forum: I&I and Metabolism, July 9-10, 2024, in Boston, and at the 3rd Annual H.C. Wainwright Virtual Kidney Conference, July 15, 2024.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company’s head office is in Edmonton, Alberta, its U.S. commercial office is in Rockville, Maryland. The Company focuses its development efforts globally.
| Last Trade: | US$7.61 |
| Daily Change: | 0.13 1.74 |
| Daily Volume: | 1,940,074 |
| Market Cap: | US$1.090B |
June 30, 2025 June 29, 2025 May 12, 2025 February 27, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
